Related Experiment Video
Updated: Jan 14, 2026
06:50
Advancements in the Metabolic Profiling of Three-Dimensional Brain Tumor Spheroids for Drug Screening
Published on: September 5, 2025
395
Pleiotropic effects of fenofibrate
V Tsimihodimos1, E Liberopoulos, M Elisaf
1Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece.
Current Pharmaceutical Design
|February 10, 2009
Summary
Fenofibrate, a fibric acid derivative, impacts lipoprotein metabolism by altering gene expression. Emerging evidence highlights its potential lipid-independent effects on atherosclerosis progression.
Area of Science:
- Pharmacology
- Cardiovascular Science
- Metabolic Research
Background:
- Fenofibrate is a widely prescribed fibric acid derivative.
- It influences lipoprotein metabolism through gene expression modulation.
- Growing research indicates potential lipid-independent actions on atherosclerosis.
Purpose of the Study:
- To review the clinical pharmacology of fenofibrate.
- To examine the evidence for fenofibrate's pleiotropic effects.
- To consolidate understanding of fenofibrate's multifaceted roles in metabolic and cardiovascular health.
Main Methods:
- Literature review of clinical pharmacology studies.
- Analysis of research on fenofibrate's effects on gene expression.
- Compilation of evidence regarding lipid-independent mechanisms.
Main Results:
- Fenofibrate modulates genes critical for lipoprotein metabolism.
- Significant evidence supports fenofibrate's lipid-independent effects on atherosclerosis.
- The drug exhibits diverse pharmacological actions beyond lipid regulation.
Conclusions:
- Fenofibrate possesses complex pharmacological properties.
- Its impact extends to lipid-independent pathways influencing atherosclerosis.
- Further research into these pleiotropic effects is warranted.
More Related Videos
Related Concept Videos
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
210
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
210
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
180
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
180
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
211
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
211
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
249
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
249
01:33Pleiotropy
43.2K
Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
43.2K
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K